Active substanceTroxerutinTroxerutin
Similar drugsTo uncover
  • Troxevasin®
    gel externally 
    AKTAVIS, LTD.     Russia
  • Troxevasin®
    capsules inwards 
  • Troxsevenol
    gel externally 
    SAMARAHEDPROM, JSC     Russia
  • Troxerutin
    gel externally 
  • Troxerutin
    capsules inwards 
    ATOLL, LLC     Russia
  • Troxerutin
    gel externally 
    ATOLL, LLC     Russia
  • Troxerutin
    capsules inwards 
    SYNTHESIS, OJSC     Russia
  • Troxerutin
    gel externally 
  • Troxerutin
    gel externally 
    GREEN DUBRAVA, CJSC     Russia
  • Troxerutin
    gel externally 
    VERTEKS, AO     Russia
  • Troxerutin
    capsules inwards 
    VERTEKS, AO     Russia
  • Troxerutin VetProm
    gel externally 
    VetProm AD     Bulgaria
  • Troxerutin Vramed
    capsules inwards 
    Sopharma, AO     Bulgaria
  • Troxerutin Vramed
    gel externally 
    Sopharma, AO     Bulgaria
  • Troxerutin Zentiva
    capsules inwards 
    Zentiva c.s.     Czech Republic
  • Troxerutin-MIC
    capsules inwards 
    MINSKINTERKAPS, UP     Republic of Belarus
  • Phlebopress®
    capsules inwards 
    ATOLL, LLC     Russia
  • Dosage form: & nbspcapsules
    Composition:

    active substance: troxerutin 300.0 mg

    Excipients: lactose monohydrate (5.0 mg), silicon colloidal dioxide (8.0 mg), Macrogol 6000 (15.0 mg), magnesium stearate (7.0 mg)
    composition of the capsule shell: titanium dioxide (2%), dye quinoline yellow (0.75%), dye sunset yellow (0.0059%), gelatin (up to 100%)
    Description:

    Hard gelatin capsules No. 1 yellow.

    The contents of the capsules are granules or a compressed mass that takes the form of a capsule, from light yellow to dark yellow.
    Pharmacotherapeutic group:venotonic and venoprotective agent
    ATX: & nbsp

    C.05.C.A   Bioflavonoids

    C.05.C.A.04   Troxerutin

    Pharmacodynamics:

    Flavonoid (derivative of routine), has P-vitamin activity; has venotonic, angioprotective, anti-inflammatory and anti-edematous action; reduces permeability and fragility of capillaries.

    Its pharmacodynamic properties are associated with the participation of trouxerutin bioflavonoids in oxidation-reduction processes and inhibition of hyaluronidase. By suppressing hyaluronidase, troxerutin stabilizes the hyaluronic acid of cell membranes and reduces their permeability. It has antioxidant activity, which prevents oxidation of ascorbic acid, adrenaline and lipids. In addition, it reduces permeability and fragility of capillaries, prevents damage to the basement membrane of endothelial cells when various factors influence it. Troxerutin reduces exudative inflammation in the vascular wall, limiting the adhesion of platelets to its surface. As a result of treatment with troxerutin, the sense of heaviness in the legs disappears, the swelling of tissues decreases, and trophicity improves.

    Pharmacokinetics:Well absorbed when applied inside. The maximum plasma concentrations are set between the second and the eighth hour. The second peak of the plasma concentration is observed at the 30th hour after taking the drug.

    It is excreted within 24 hours mainly with bile (up to 70%), and an insignificant part (up to 25%) - with urine.

    Indications:

    - Chronic venous insufficiency

    - Varicose veins, varicose dermatitis, varicose ulcers

    - Thrombophlebitis and postthrombotic syndrome

    - Hemorrhoids (for relief of symptoms)

    - Post-traumatic swelling of soft tissues

    - In the complex treatment of diabetic retinopathy

    Contraindications:- Supersensitivity to trokserutinu or auxiliary substances included in preparation
    -Stomach ulcer, duodenum and chronic gastritis in phase exacerbations
    - Pregnancy (1st trimester)
    - Children under 18 years old
    - Intolerance to galactose, lactase insufficiency or glucose-galactose syndrome malabsorption
    Carefully:Renal failure (with prolonged use)
    Pregnancy and lactation:

    In the first 3 months of pregnancy, the use of a medicinal product is not recommended troxerutin. During the second and third trimester of pregnancy and breastfeeding, the use of the drug requires taking into account the ratio of expected benefits to the mother and the potential risk to the child.,

    Dosing and Administration:

    Capsules are taken orally during meals.

    The initial dose for adults is 1 capsule 2-3 times a day until the symptoms disappear completely. For maintenance treatment, a dose of 1 capsule per day for 3 to 4 weeks is recommended.

    The experience of using the drug in children is limited, so it is not recommended to prescribe it to children.

    Side effects:

    Side effects are rare:

    - from the gastrointestinal tract: nausea, vomiting, stomach pain, flatulence, diarrhea and erosive-ulcerative lesions of the gastrointestinal tract;

    - from the skin: erythema and itching;

    - common disorders: headache.

    Overdose:

    There is no evidence of an overdose of the drug when it is administered orally.

    Interaction:There is no evidence of adverse interactions of troxerutin with other drugs.
    Special instructions:

    Troxerutin is ineffective in edema caused by concomitant diseases of the liver, kidneys and heart.

    Dye E 110 can cause allergic reactions.

    Effect on the ability to drive transp. cf. and fur:

    The use of the drug does not affect the ability to drive vehicles and work with machines.

    Form release / dosage:

    Capsules 300 mg.

    Packaging:

    For 10 capsules in a blister of colorless PVC / aluminum foil.

    5 blisters together with instructions for use in a pack of cardboard.

    Storage conditions:

    5 years. Do not use after the expiration date printed on the package.

    Shelf life:

    In dry, the dark place at a temperature of no higher than 25 C.

    Keep out of the reach of children!

    Terms of leave from pharmacies:Without recipe
    Registration number:П N011640 / 02
    Date of registration:08.08.2011
    The owner of the registration certificate:Sopharma, AOSopharma, AO Bulgaria
    Manufacturer: & nbsp
    Representation: & nbspSOFARMA SA SOFARMA SA Bulgaria
    Information update date: & nbsp21.10.2015
    Illustrated instructions
      Instructions
      Up